AR031969A1 - Agente preventivo y/o terapeutico para enfermedades inflamatorias de las vias respiratorias - Google Patents

Agente preventivo y/o terapeutico para enfermedades inflamatorias de las vias respiratorias

Info

Publication number
AR031969A1
AR031969A1 ARP010106024A ARP010106024A AR031969A1 AR 031969 A1 AR031969 A1 AR 031969A1 AR P010106024 A ARP010106024 A AR P010106024A AR P010106024 A ARP010106024 A AR P010106024A AR 031969 A1 AR031969 A1 AR 031969A1
Authority
AR
Argentina
Prior art keywords
preventive
therapeutic agent
inflammatory diseases
respiratory tract
prenadien
Prior art date
Application number
ARP010106024A
Other languages
English (en)
Original Assignee
Hisamitsu Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisamitsu Medical Co Ltd filed Critical Hisamitsu Medical Co Ltd
Publication of AR031969A1 publication Critical patent/AR031969A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Agente preventivo y/o terapéutico para enfermedades inflamatorias de las vías respiratorias, su sustancia activa es 17-ciclopropancarboxilato de 9-fluoro-11beta, 17,21-trihidroxi-16alfa-metil-1,4-prenadien-3,20-diona (compuesto 1) o 21-ciclohexancarboxilato 17-ciclopropancarboxilato de 9-fluoro-11beta, 17,21-trihidroxi-16alfa-metil-1,4-prenadien-3,20-diona (compuesto 2). Estos compuestos inhiben de manera continuada la inflamacion de las vías respiratorias e hiperreflejos de la reaccion de las vías respiratorias, y muestran también alta selectividad local y ningun cuerpo como efecto total en caso de aplicacion directa a las vías respiratorias. Por lo tanto, son clínicamente muy importantes como agente preventivo y/o terapéutico para enfermedades inflamatorias de las vías respiratorias siendo aptas para una administracion prolongada y de alta seguridad.
ARP010106024A 2000-12-22 2001-12-26 Agente preventivo y/o terapeutico para enfermedades inflamatorias de las vias respiratorias AR031969A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000390941 2000-12-22

Publications (1)

Publication Number Publication Date
AR031969A1 true AR031969A1 (es) 2003-10-08

Family

ID=18857198

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP010106024A AR031969A1 (es) 2000-12-22 2001-12-26 Agente preventivo y/o terapeutico para enfermedades inflamatorias de las vias respiratorias
ARP140103518A AR097737A2 (es) 2000-12-22 2014-09-23 Agente preventivo y/o terapéutico para enfermedades inflamatorias del tracto respiratorio

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP140103518A AR097737A2 (es) 2000-12-22 2014-09-23 Agente preventivo y/o terapéutico para enfermedades inflamatorias del tracto respiratorio

Country Status (16)

Country Link
US (1) US7214672B2 (es)
EP (1) EP1344526B1 (es)
JP (1) JP3691487B2 (es)
KR (1) KR100833157B1 (es)
CN (2) CN101518537A (es)
AR (2) AR031969A1 (es)
AT (1) ATE396733T1 (es)
CA (1) CA2438799C (es)
DE (1) DE60134267D1 (es)
DK (1) DK1344526T3 (es)
ES (1) ES2305029T3 (es)
MX (1) MXPA03005660A (es)
PE (1) PE20020793A1 (es)
PT (1) PT1344526E (es)
TW (1) TWI290145B (es)
WO (1) WO2002051422A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0113042B8 (pt) * 2000-08-05 2021-05-25 Glaxo Group Ltd composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
GB0019172D0 (en) * 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
BR0209271A (pt) * 2001-04-30 2004-06-15 Glaxo Group Ltd Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto
US20040248867A1 (en) * 2001-06-12 2004-12-09 Keith Biggadike Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
JP3691459B2 (ja) * 2002-06-14 2005-09-07 久光メディカル株式会社 粉末状吸入剤組成物
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
EP1645266A1 (en) * 2004-10-08 2006-04-12 Hisamitsu Medical Co., Ltd. Aqueous suspension for nasal drops
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639434A (en) 1967-02-02 1972-02-01 Boots Pure Drug Co Ltd 17-acyloxysteroids and their manufacture
SE418294B (sv) 1974-03-27 1981-05-18 Plurichemie Anstalt Sett att framstella en 16alfa- eller 16beta-9alfa-klor eller -fluorsteroidester
US4933168A (en) * 1975-05-27 1990-06-12 Syntex Pharmaceuticals International Limited Stable, crystalline flunisolide
IL66432A0 (en) 1981-08-04 1982-12-31 Plurichemie Anstalt Process for the preparation of steroidal esters
JPH07116215B2 (ja) * 1989-04-19 1995-12-13 エスエス製薬株式会社 新規なステロイド化合物
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias

Also Published As

Publication number Publication date
EP1344526B1 (en) 2008-05-28
EP1344526A1 (en) 2003-09-17
EP1344526A4 (en) 2005-03-16
CA2438799C (en) 2009-09-01
DE60134267D1 (de) 2008-07-10
KR100833157B1 (ko) 2008-05-28
ATE396733T1 (de) 2008-06-15
PE20020793A1 (es) 2002-09-06
CN1481246A (zh) 2004-03-10
DK1344526T3 (da) 2008-09-15
AR097737A2 (es) 2016-04-13
WO2002051422A1 (fr) 2002-07-04
CA2438799A1 (en) 2002-07-04
MXPA03005660A (es) 2004-12-03
ES2305029T3 (es) 2008-11-01
TWI290145B (en) 2007-11-21
CN101518537A (zh) 2009-09-02
JPWO2002051422A1 (ja) 2004-04-22
US20040053904A1 (en) 2004-03-18
JP3691487B2 (ja) 2005-09-07
US7214672B2 (en) 2007-05-08
PT1344526E (pt) 2008-06-18
KR20030064414A (ko) 2003-07-31

Similar Documents

Publication Publication Date Title
AR097737A2 (es) Agente preventivo y/o terapéutico para enfermedades inflamatorias del tracto respiratorio
DE69933208D1 (de) Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt
BR0012450A (pt) Benzimidazóis substituìdos
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
IL172705A0 (en) Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
CY1105849T1 (el) Χρηση αντισηπτικων στην εμπορικη κατασκευη φαρμακευτικου παρασκευασματος προς αποτροπη ή θepαπεια εναντι φλεγμονων εντος του ανθρωπινου σωματος
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
BRPI0506705A (pt) composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
DE60219314D1 (de) Halogenhaltige zusammensetzung, verfahren zu deren herstellung und deren verwendung
ES2139673T3 (es) Utilizacion de norastemizol para el tratamiento de rinitis alergica.
JP2012516315A (ja) 乾癬の処置
US20130226136A1 (en) Molecules for the Photodynamic Treatment of Tumors and Hyperplasias
ES2257282T3 (es) Melagatran para el tratamiento de inflamacion.
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
AR039409A1 (es) Composicion farmaceutica en polvo seco para inhalacion, fabricacion y uso.
ES2251623T3 (es) Dispositivo de cuidado de heridas.
DE60043886D1 (de) Formulierungen mit povidon-iod zur behandlung von wunden
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
ATE273682T1 (de) Topische formulierungen, die hautpenetrations- mittel enthalten, und ihre verwendung
BR0115881A (pt) Emprego de compostos ciclohexanona substituìdos de 6-dimetilaminometil-1-fenil para a terapia da incontinência urinária
BR0009327A (pt) Composição farmacêutica para a terapia de sintomas do trato urinário inferior
BRPI0410576A (pt) composto quìmico, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou condição de um corpo de animal vivo
JP4361789B2 (ja) 体表の過剰増殖疾患の処置

Legal Events

Date Code Title Description
FC Refusal